Medivir: Phase I part of the liver cancer trial completed
Research Note
2023-06-02
16:03
Redeye comments on the conclusion of the phase I part of the ongoing phase I/IIa study of fostroxacitabine bralpamide in liver cancer (HCC). Medivir will not continue with the expansion cohort in the anti-PD-1 arm. We update our Base Case.
RR
Richard Ramanius
Disclosures and disclaimers